AVITA Medical Q2 revenue $18.4M (+21% YoY); slashes FY2025 revenue guidance to $76M-$81M, delays profitability to 2026

AVITA Medical, Inc.

2025-Q2 EPS reported -$0.90 revenue$36,932,000

Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.
FY2025 revenue guidance reduced to $76M-$81M (prior $100M-$106M) due to MAC payment backlog affecting RECELL demand.
Fifth amendment to OrbiMed credit agreement: TTM revenue covenants lowered through Q2 2026; 400,000 common shares issued in lieu of cash fee.
Michael Tarnoff appointed to Board of Directors; adds healthcare leadership experience.
Clinical highlight: RECELL reduces hospital stays 36%; CMS NTAP approved for inpatient trauma wounds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.